- Home
- AIM vs RYDE Comparison
AIM vs RYDE Comparison
Compare AIM & RYDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- RYDE
- Stock Information
- Founded
- AIM 1966
- RYDE 2014
- Country
- AIM United States
- RYDE Singapore
- Employees
- AIM N/A
- RYDE N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- RYDE
- Sector
- AIM Health Care
- RYDE
- Exchange
- AIM Nasdaq
- RYDE NYSE
- Market Cap
- AIM 15.9M
- RYDE 13.9M
- IPO Year
- AIM N/A
- RYDE 2024
- Fundamental
- Price
- AIM $0.22
- RYDE $0.45
- Analyst Decision
- AIM Strong Buy
- RYDE Strong Buy
- Analyst Count
- AIM 2
- RYDE 1
- Target Price
- AIM $3.00
- RYDE $9.00
- AVG Volume (30 Days)
- AIM 295.4K
- RYDE 565.4K
- Earning Date
- AIM 11-15-2024
- RYDE 11-22-2024
- Dividend Yield
- AIM N/A
- RYDE N/A
- EPS Growth
- AIM N/A
- RYDE N/A
- EPS
- AIM N/A
- RYDE N/A
- Revenue
- AIM $190,000.00
- RYDE $5,761,982.00
- Revenue This Year
- AIM N/A
- RYDE $2.61
- Revenue Next Year
- AIM $1,086.80
- RYDE $21.90
- P/E Ratio
- AIM N/A
- RYDE N/A
- Revenue Growth
- AIM N/A
- RYDE N/A
- 52 Week Low
- AIM $0.21
- RYDE $0.44
- 52 Week High
- AIM $0.62
- RYDE $22.49
- Technical
- Relative Strength Index (RSI)
- AIM 35.93
- RYDE N/A
- Support Level
- AIM $0.24
- RYDE N/A
- Resistance Level
- AIM $0.27
- RYDE N/A
- Average True Range (ATR)
- AIM 0.02
- RYDE 0.00
- MACD
- AIM -0.00
- RYDE 0.00
- Stochastic Oscillator
- AIM 7.49
- RYDE 0.00
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About RYDE RYDE GROUP LTD
Ryde Group Ltd is a company providing a super mobility app offering ultimate convenience and reliability for their customers through multiple mobility tools that can be accessed and function seamlessly out of a single app. The company operates in the following segments such as being mobility where it provides on-demand and scheduled carpooling and ride-hailing services, matching riders to driver partners; and quick commerce where it provides on-demand, scheduled, and multi-stop parcel delivery services.